• / Free eNewsletters & Magazine
  • / My Account
Home>European Commission

European Commission

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  1. EU Clears Dow-DuPont Deal With Conditions -- Update

    EU Clears Dow-DuPont Deal With Conditions -- Update

  2. Inventiva: Acceleration of the Clinical Development Activities and Consolidation of the Financial Position in 2016

    Inventiva: Acceleration of the Clinical Development Activities and Consolidation of the Financial Position in 2016

  3. XELJANZ® (tofacitinib citrate) Receives Marketing Authorisation in the European Union for the Treatment of Moderate to Severe Active Rheumatoid Arthritis (RA)

    XELJANZ® (tofacitinib citrate) Receives Marketing Authorisation in the European Union for the Treatment of Moderate to Severe Active Rheumatoid Arthritis (RA)

  4. EU Clears Dow-DuPont Deal With Conditions

    EU Clears Dow-DuPont Deal With Conditions

  5. Dow-DuPont deal gets EU clearance with conditions

    Dow-DuPont deal gets EU clearance with conditions

  6. EU Taking Second Look at Past Deals -- WSJ

    EU Taking Second Look at Past Deals -- WSJ

  7. European Medicines Agency’s CHMP Recommends Approval of Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Relapsed or Refractory Classical Hodgkin Lymphoma

    European Medicines Agency’s CHMP Recommends Approval of Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Relapsed or Refractory Classical Hodgkin Lymphoma

  8. Pfizer Receives Positive CHMP Opinion for TRUMENBA® for Prevention of Meningococcal Group B Disease

    Pfizer Receives Positive CHMP Opinion for TRUMENBA® for Prevention of Meningococcal Group B Disease

  9. Pope Francis Urges EU Unity After Greek Row

    Pope Francis Urges EU Unity After Greek Row

  10. European Hopes Dim for a Brexit Trade Pact

    European Hopes Dim for a Brexit Trade Pact

12345

©2017 Morningstar Advisor. All right reserved.